These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36225932)

  • 1. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
    Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
    Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
    Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients.
    Zhang WT; Gong YM; Zhang CY; Pan JS; Huang T; Li YX
    Biomed Res Int; 2022; 2022():9196540. PubMed ID: 36105937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
    Zeng S; Zhang H; Zhang D; Hu X; Song L
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FECH Expression Correlates with the Prognosis and Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.
    Zhong G; Li Q; Luo Y; Liu Y; Liu D; Li B; Wang T
    J Oncol; 2022; 2022():8943643. PubMed ID: 36059798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
    Wang L; Cao Y; Guo W; Xu J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma.
    Mou Y; Wu J; Zhang Y; Abdihamid O; Duan C; Li B
    BMC Cancer; 2021 Jan; 21(1):18. PubMed ID: 33402128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma.
    Zheng B; Wang S; Yuan X; Zhang J; Shen Z; Ge C
    BMC Urol; 2023 May; 23(1):82. PubMed ID: 37138262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis.
    Huang X; Wang T; Ye J; Feng H; Zhang X; Ma X; Wang B; Huang Y; Zhang X
    Front Genet; 2022; 13():994741. PubMed ID: 36186457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma.
    Jiang A; Ye J; Zhou Y; Zhu B; Lu J; Ge S; Qu L; Xiao J; Wang L; Cai C
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
    Dai L; Zhou P; Lyu L; Jiang S
    BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
    Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
    Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
    Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
    Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.